Cephalon Provides Update On Regulatory Status Of The FENTORA Supplemental New Drug Application
Cephalon, Inc., (Nasdaq: CEPH) announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) for FENTORA(R) (fentanyl buccal tablet) [C-II] for the management of breakthrough pain in opioid-tolerant patients with chronic pain. In addition, the FDA notified the Company that it will convene an advisory committee panel on May 6, 2008, to consider this application.
More: continued here
Filed under: Pain / Anesthetics on January 29th, 2008